Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors while in the central nervous technique, conolidine modulates alternate molecular targets. A Science Improvements research discovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://mikhailn863kmn4.blog-mall.com/profile